Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2018 Feb;71(2):163-165.
doi: 10.1053/j.ajkd.2017.10.005. Epub 2017 Dec 6.

Improving Carboplatin Dosing Based on Estimated GFR

Jan H Beumer  1 , Lesley A Inker  2 , Andrew S Levey  3
Affiliations
Editorial

Improving Carboplatin Dosing Based on Estimated GFR

Jan H Beumer et al. Am J Kidney Dis. 2018 Feb.
No abstract available

PubMed Disclaimer

Conflict of interest statement

Authors’ disclosures of potential conflicts of interest:

Employment or Leadership Position: None; Consultant or Advisory Role: Tricidea (LAI) ; Stock Ownership: None; Honoraria: None; Research Funding: None; Expert Testimony: None; Other Remuneration: None: Other: Drs. Levey and Inker led the development of the CKD-EPI equation. Drs. Levey and Inker have a provisional patent filed 8/15/2014 –”Precise estimation of glomerular filtration rate from multiple biomarkers” PCT/US2015/044567.

Figures

Figure 1:
Figure 1:. Determinants of carboplatin exposure, toxicity and response in an individual patient.
Carboplatin dose is determined using the Calvert formula which requires the clinician to determine the target AUC and GFR. The target AUC is determined by tumor type and patient characteristics. GFR can be determined using measured or estimated GFR. Blue shaded cells indicate quantities determined by equations; green shaded cells indicate quantities decided by clinicians; purple shaded cells indicate true quantities and subsequent events.
See this image and copyright information in PMC

Comment on

References

    1. Levey AS, Inker LA. Assessment of Glomerular Filtration Rate in Health and Disease: A State of the Art Review. Clinical pharmacology and therapeutics. 2017;102:405–419. - PubMed
    1. Janowitz T, Williams EH, Marshall A, et al. New Model for Estimating Glomerular Filtration Rate in Patients With Cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2017:JCO2017727578. - PMC - PubMed
    1. Ho GY, Woodward N, Coward JI. Cisplatin versus carboplatin: comparative review of therapeutic management in solid malignancies. Critical reviews in oncology/hematology. 2016;102:37–46. - PubMed
    1. Jodrell DI, Egorin MJ, Canetta RM, et al. Relationships between carboplatin exposure and tumor response and toxicity in patients with ovarian cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 1992;10:520–528. - PubMed
    1. Oliver RT, Mead GM, Rustin GJ, et al. Randomized trial of carboplatin versus radiotherapy for stage I seminoma: mature results on relapse and contralateral testis cancer rates in MRC TE19/EORTC 30982 study (ISRCTN27163214). Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2011;29:957–962. - PubMed

LinkOut - more resources